<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02567955</url>
  </required_header>
  <id_info>
    <org_study_id>HPV 2355</org_study_id>
    <nct_id>NCT02567955</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Gardasil-9 and Cervarix</brief_title>
  <official_title>Immunogenicity and Safety of Gardasil-9 and Cervarix When Administered to 9-10-year-old Subjects According to 0-6 Month Schedule</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A ninevalent HPV vaccine (Gardasil-9) has been recently approved for clinical use. No data on
      immunogenicity and safety of interchangeable use of the ninevalent and the bivalent vaccine
      (Cervarix) are available. The main objective of this study is to assess the immunogenicity of
      ninevalent and bivalent HPV vaccines when administered to 9-10-year-old girls and boys
      according to 0-6 month schedule.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proportion of subjects with detectable antibodies and antibody geometrical mean titers to
      9 HPV genotypes included in the Gardasil-9 vaccine will be assessed 1 and 6 months post-first
      dose and 1, 18 and 36 months post-second dose of vaccine.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of proportion of subjects with detectable antibodies to 9 HPV genotypes included in the Gardasil-9 vaccine observed in two study arms</measure>
    <time_frame>36 months post-second dose of vaccine</time_frame>
    <description>A Luminex Total IgG assay will be used to assess the presence of antibodies and antibody titers to 9 HPV genotypes included in the Gardasil-9 vaccine. Luminex Units will be used for the antibody titers assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of tolerability profile of Gardasil-9 and Cervarix</measure>
    <time_frame>During 5 days after each vaccine dose administration.</time_frame>
    <description>Local and general symptoms observed after each vaccine dose will be assessed by using a standardized diary card. Proportion of subjects who reported local and/or general symptoms will be compared.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">370</enrollment>
  <condition>HPV Vaccines Immunogenicity and Safety</condition>
  <arm_group>
    <arm_group_label>Gardasil-9 and Gardasil-9</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this arm will receive two doses of Gardasil-9 according to 0-6 month schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cervarix and Gardasil-9</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this arm will receive one dose of Cervarix and one dose of Gardasil-9 according to 0-6 month schedule</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gardasil-9 and Gardasil-9</intervention_name>
    <description>Subjects will receive two standard doses of Gardasil-9 (0.5 ml)</description>
    <arm_group_label>Gardasil-9 and Gardasil-9</arm_group_label>
    <other_name>HPV vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cervarix and Gardasil-9</intervention_name>
    <description>Subjects will receive a standard dose of Cervarix (0.5 ml) and a standard dose of Gardasil-9 (0.5 ml)</description>
    <arm_group_label>Cervarix and Gardasil-9</arm_group_label>
    <other_name>HPV vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  9-10-year-old girls and boys

        Exclusion Criteria:

          -  previously received an HPV vaccine

          -  immunosuppressed

          -  known allergy to a vaccine component
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vladimir Gilca, MD, PhD</last_name>
    <phone>4186667000</phone>
    <phone_ext>510</phone_ext>
    <email>vladimir.gilca@inspq.qc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chantal Sauvageau, MD, MSc</last_name>
    <phone>4186667000</phone>
    <email>chantal.sauvageau@inspq.qc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ã‰quipe de recherche en vaccination</name>
      <address>
        <city>Quebec</city>
        <zip>G1E7G9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir Gilca, MD, PhD</last_name>
      <phone>418 666 7000</phone>
      <phone_ext>510</phone_ext>
      <email>vladimir.gilca@inspq.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>France Bouchard, RN</last_name>
      <phone>418 666 7000</phone>
      <phone_ext>323</phone_ext>
      <email>france.bouchard@ssss.gouv.qc.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2015</study_first_submitted>
  <study_first_submitted_qc>October 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2015</study_first_posted>
  <last_update_submitted>October 1, 2015</last_update_submitted>
  <last_update_submitted_qc>October 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV vaccines, interchangeable use</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

